Group 1 - Alto Neuroscience, Inc. (ANRO) shares have increased by 162.9% over the past four weeks, closing at $10.2, with a mean price target of $13 indicating a potential upside of 27.5% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $2.45, where the lowest estimate is $10.00 (2% decline) and the highest is $16.00 (56.9% increase) [2] - Analysts show a consensus that ANRO will report better earnings than previously estimated, which supports the potential for stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ANRO has increased by 0.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - ANRO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Insights - Alto Neuroscience, Inc. has announced a private placement financing agreement to raise approximately $50 million in gross proceeds [1] Company Summary - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] - The financing involves institutional and accredited investors [1]

Core Insights - Alto Neuroscience, Inc. is accelerating the development of ALTO-207 for treatment-resistant depression (TRD) following a successful FDA meeting [1] - The company announced a $50 million private placement to support the expanded development of ALTO-207 [1] Company Overview - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] Financial Aspects - The recent $50 million private placement will facilitate the advancement of ALTO-207 [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Alto Neuroscience, Inc. (NYSE:ANRO) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][6]. Company Overview - Alto Neuroscience, Inc. is facing scrutiny following a class action complaint filed on July 21, 2025, concerning the period from February 2, 2024, to October 22, 2024 [1]. - The complaint alleges that the Offering Documents related to Alto's IPO were negligently prepared and that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated [6]. Financial Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [6].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims against Alto Neuroscience, Inc. officers and directors for possible breaches of fiduciary duties [1] Group 1: Allegations of Misconduct - A federal securities fraud class action complaint has been filed against Alto Neuroscience, Inc., alleging that the company made materially false and misleading statements regarding its business and operations [2] - The complaint specifically claims that ALTO-100 was less effective in treating Major Depressive Disorder (MDD) than represented, and that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated [2] - As a result of these misrepresentations, the company's business and financial prospects were also overstated, leading to materially false public statements [2] Group 2: Actions for Shareholders - Shareholders may pursue changes to the company's corporate governance practices, seek recovery of funds, and request a court-approved incentive award at no cost [3] - Interested parties can join the action through a provided link or by contacting Johnson Fistel, PLLP directly [3] Group 3: About the Law Firm - Johnson Fistel, PLLP is a nationally recognized law firm that represents individual and institutional investors in shareholder derivative and securities class action lawsuits [4]

Core Viewpoint - Alto Neuroscience, Inc. has received Fast Track designation from the U.S. FDA for its drug ALTO-101, aimed at treating cognitive impairment associated with schizophrenia, a condition currently lacking approved treatments [1] Company Summary - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders [1] Industry Summary - Cognitive impairment associated with schizophrenia (CIAS) is identified as a core feature of schizophrenia, highlighting a significant unmet medical need in the treatment landscape [1]

Group 1 - A class action has been filed on behalf of investors who purchased or acquired Alto Neuroscience, Inc. common stock related to its initial public offering (IPO) [1] - The IPO was conducted on or about February 2, 2024, and the class action covers securities acquired between February 2, 2024, and October 22, 2024 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the lead plaintiff deadline for a class action lawsuit related to the company's initial public offering and subsequent securities purchases [1]. Group 1: Class Action Details - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [7]. Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [7]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than the company had indicated, leading to overstated clinical, regulatory, and commercial prospects [7]. Stock Performance Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [7]. Next Steps for Investors - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 19, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and specializes in commercial and securities litigation [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against Alto Neuroscience - The complaint alleges that the company's product ALTO-100 was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical, regulatory, and commercial prospects [4]. - As a result of these misleading statements, Alto's business and financial prospects were also overstated, impacting the accuracy of the company's public statements [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [6].